Civica Rx, a nonprofit drug company founded by U.S. health systems, plans to launch an insulin glargine product in January through an expanded partnership with Biocon Biologics.
Under the multi-year agreement, Biocon Biologics will manufacture and supply the insulin — interchangeable with Lantus — while Civica Rx will distribute and sell it under its own label, according to an Oct. 16 news release shared with Becker’s. In California, the product will carry the CalRx brand. The drug will be priced at $45 per box of five pre-filled pens, with a recommended retail price of no more than $55.
Biocon Biologics will continue to sell its own FDA-approved biosimilar insulin glargine-yfgn separately.
